• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Treating Helicobacter pylori effectively while minimizing misuse of antibiotics.有效治疗幽门螺杆菌，同时最大限度减少抗生素滥用。
Cleve Clin J Med. 2017 Apr;84(4):310-318. doi: 10.3949/ccjm.84a.14110.
2
Practical Aspects in Choosing a Helicobacter pylori Therapy.选择幽门螺杆菌治疗方法的实际考量
Gastroenterol Clin North Am. 2015 Sep;44(3):519-35. doi: 10.1016/j.gtc.2015.05.004. Epub 2015 Jun 19.
3
Current treatment of Helicobacter pylori infection.幽门螺杆菌感染的当前治疗方法。
Med Clin (Barc). 2017 Jan 6;148(1):20-22. doi: 10.1016/j.medcli.2016.10.026. Epub 2016 Dec 1.
4
Treatment of Helicobacter pylori infection 2011.2011 年幽门螺杆菌感染治疗。
Helicobacter. 2011 Sep;16 Suppl 1:53-8. doi: 10.1111/j.1523-5378.2011.00881.x.
5
Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance.抗生素耐药性不断增加的时代下针对[具体病症，原文缺失]的新型有效治疗方案
Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017.
6
The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial.益生菌在幽门螺杆菌根除治疗期间对肠道微生物群的影响：随机对照试验。
Helicobacter. 2016 Jun;21(3):165-74. doi: 10.1111/hel.12270. Epub 2015 Sep 23.
7
Persistent Helicobacter pylori infection after a course of antimicrobial therapy-what's next?抗菌治疗疗程后幽门螺杆菌持续感染——接下来该怎么办？
Clin Gastroenterol Hepatol. 2008 Oct;6(10):1086-90. doi: 10.1016/j.cgh.2008.05.009. Epub 2008 Jul 17.
8
Helicobacter pylori eradication - an update on the latest therapies.幽门螺杆菌根除——最新疗法的进展
Aust Fam Physician. 2014 May;43(5):301-5.
9
Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.益生菌能否提高幽门螺杆菌三联根除疗法的有效性和安全性？一项前瞻性随机研究。
Vojnosanit Pregl. 2016 Nov;73(11):1044-9. doi: 10.2298/VSP150415127G.
10
Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.基于 vonoprazan 的三联疗法与基于药敏的质子泵抑制剂三联疗法根除幽门螺杆菌的非劣效性研究。
Ann Clin Microbiol Antimicrob. 2018 Jun 28;17(1):29. doi: 10.1186/s12941-018-0281-x.

引用本文的文献

1
First regional consensus on the management of infection in the Middle East.中东地区关于感染管理的首个区域共识。
World J Gastroenterol. 2025 Jul 21;31(27):107138. doi: 10.3748/wjg.v31.i27.107138.
2
Overcoming antibiotic-resistant infection: Current challenges and emerging approaches.克服抗生素耐药性感染：当前挑战与新出现的方法。
World J Gastroenterol. 2025 Mar 14;31(10):102289. doi: 10.3748/wjg.v31.i10.102289.
3
Cloning, Expression, Purification and Biological Activity Analysis of Recombinant Helicobacter pylori FabI as a Drug Target.重组幽门螺杆菌FabI作为药物靶点的克隆、表达、纯化及生物学活性分析
Mol Biotechnol. 2025 Feb 27. doi: 10.1007/s12033-025-01411-x.
4
Targeting Through the "Muco-Microbiotic Layer" Lens: The Challenge of Probiotics and Microbiota Nanovesicles.从“黏液-微生物层”视角看靶向性：益生菌与微生物群纳米囊泡面临的挑战
Nutrients. 2025 Feb 3;17(3):569. doi: 10.3390/nu17030569.
5
Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA-Labeled Dosing Frequency of RHB-105 Low-Dose Rifabutin Triple Therapy for Helicobacter pylori Eradication.基于生理的药代动力学建模与模拟，以支持RHB - 105低剂量利福布汀三联疗法用于根除幽门螺杆菌时FDA批准的给药频率的变更。
J Clin Pharmacol. 2025 Jun;65(6):779-786. doi: 10.1002/jcph.6178. Epub 2025 Jan 2.
6
Overcoming the effects of increasing antimicrobial resistance on therapy.克服抗菌药物耐药性增加对治疗的影响。
Expert Rev Gastroenterol Hepatol. 2024 Nov;18(11):705-711. doi: 10.1080/17474124.2024.2435520. Epub 2024 Dec 11.
7
Assessment of cytotoxin-associated Gene A (Cag A) protein and its association with ferritin and vitamin B12 deficiencies among adult healthy asymptomatic residents in Sharjah, United Arab Emirates.阿拉伯联合酋长国沙迦成年健康无症状居民中细胞毒素相关基因A（Cag A）蛋白的评估及其与铁蛋白和维生素B12缺乏的关联。
Heliyon. 2024 May 29;10(11):e32141. doi: 10.1016/j.heliyon.2024.e32141. eCollection 2024 Jun 15.
8
anti- activity and the underlining mechanism of an empirical herbal formula - Hezi Qingyou.经验性中药配方诃子清油的抗炎活性及潜在机制
Front Microbiol. 2024 Feb 19;15:1355460. doi: 10.3389/fmicb.2024.1355460. eCollection 2024.
9
Controversies regarding management of Helicobacter pylori infections.关于幽门螺杆菌感染处理的争议。
Curr Opin Gastroenterol. 2023 Nov 1;39(6):482-489. doi: 10.1097/MOG.0000000000000981. Epub 2023 Sep 5.
10
MAT Gain of Activity Mutation in Is Associated with Resistance to MTAN Transition State Analogues.MAT 活性突变增益与 MTAN 过渡态类似物耐药性相关。
ACS Infect Dis. 2023 Apr 14;9(4):966-978. doi: 10.1021/acsinfecdis.2c00644. Epub 2023 Mar 15.

本文引用的文献

1
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.幽门螺杆菌根除的挽救治疗：铋剂四联疗法中阿莫西林或四环素的随机非劣效性试验
Am J Gastroenterol. 2016 Dec;111(12):1736-1742. doi: 10.1038/ajg.2016.443. Epub 2016 Sep 27.
2
Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.使用质子泵抑制剂或钾离子竞争性酸阻滞剂根除幽门螺杆菌：克拉霉素耐药性的影响
Dig Dis Sci. 2016 Nov;61(11):3215-3220. doi: 10.1007/s10620-016-4305-0. Epub 2016 Sep 22.
3
Epidemiology of Helicobacter pylori infection.幽门螺杆菌感染的流行病学
Helicobacter. 2016 Sep;21 Suppl 1:3-7. doi: 10.1111/hel.12332.
4
The Toronto Helicobacter pylori Consensus in Context.多伦多幽门螺杆菌共识解读
Gastroenterology. 2016 Jul;151(1):9-12. doi: 10.1053/j.gastro.2016.05.009. Epub 2016 May 20.
5
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.《多伦多成人幽门螺杆菌感染治疗共识》。
Gastroenterology. 2016 Jul;151(1):51-69.e14. doi: 10.1053/j.gastro.2016.04.006. Epub 2016 Apr 19.
6
Helicobacter pylori therapy: a paradigm shift.幽门螺杆菌治疗：范式转变。
Expert Rev Anti Infect Ther. 2016 Jun;14(6):577-85. doi: 10.1080/14787210.2016.1178065. Epub 2016 May 3.
7
Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues.沃克帕唑根除幽门螺杆菌治疗：伦理与解读问题。
Gut. 2017 Feb;66(2):384-386. doi: 10.1136/gutjnl-2016-311796. Epub 2016 Apr 7.
8
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.沃克（富马酸沃克替唑胺），一种新型钾离子竞争性酸阻滞剂，作为一线和二线三联疗法的组成部分用于根除幽门螺杆菌：一项III期随机双盲研究。
Gut. 2016 Sep;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304. Epub 2016 Mar 2.
9
Role of bismuth in improving Helicobacter pylori eradication with triple therapy.铋在三联疗法提高幽门螺杆菌根除率中的作用。
Gut. 2016 May;65(5):870-8. doi: 10.1136/gutjnl-2015-311019. Epub 2016 Feb 4.
10
Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies.含利福布汀三联疗法和含利福布汀与铋剂四联疗法用于幽门螺杆菌感染三线治疗的两项初步研究。
Helicobacter. 2016 Oct;21(5):375-81. doi: 10.1111/hel.12296. Epub 2016 Jan 25.

有效治疗幽门螺杆菌，同时最大限度减少抗生素滥用。

Treating Helicobacter pylori effectively while minimizing misuse of antibiotics.

机构信息

Professor, Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan.

GI Division, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institution of Digestive Disease, Shanghai, China.

出版信息

Cleve Clin J Med. 2017 Apr;84(4):310-318. doi: 10.3949/ccjm.84a.14110.

DOI:10.3949/ccjm.84a.14110
PMID:28388387
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6905081/
Abstract

Experts now recommend that all Helicobacter pylori infections be eradicated unless there are compelling reasons not to. As with other infectious diseases, effective therapy should be based on susceptibility.

摘要

专家们现在建议，除非有强烈的不治疗理由，否则应根除所有幽门螺杆菌感染。与其他传染病一样，有效的治疗应基于药敏性。